If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
142
results.
Updated on
20/07/2025 [07:03:00]
Results 100 to 125 of 142
Absstract of: KR20250077973A
본 발명은 개체의 아르기닌(Arginine) 대사경로 활성화를 확인하는 단계;를 포함하는, COVID-19 코로나바이러스 변이주 감염의 모니터링 방법에 관한 것으로, 본 발명의 모니터링 방법은 COVID-19 코로나바이러스 변이주 감염 개체에서 아르기닌 대사에 관여하는 전사체 및 대사체의 변화를 확인함으로써, 효과적으로 COVID-19 코로나바이러스 변이주 감염을 진단할 수 있다.
Absstract of: AU2023361023A1
The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.
Absstract of: AU2023356620A1
The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.
Absstract of: NZ795032A
Disclosed is a method for improving the immunogenicity of a protein/peptide antigen, the method comprising conjugating a protein/peptide antigen with a sugar to form a sugar-protein/peptide antigen conjugate, which has improved immunogenicity compared to an unconjugated protein/peptide antigen. In particular, the method involves conjugating a pathogen, such as a viral surface protein antigen or a fragment thereof selected from human respiratory syncytial virus glycoprotein G (RSV-gpG), hepatitis C virus envelope glycoprotein E1 protein (HCV-E1), hepatitis C virus envelope E2 protein (HCV-E2), influenza B hemagglutinin protein (Flu-B-HA1), influenza A H5N1 hemagglutinin (H5N1-HA), ebola virus glycoprotein (Ebola-GP), ebola virus hlycoprotein GP1 (Ebola-GP1), zika virus envelope protein (ZIKV-E), and/or coronavirus spike protein, with a polysaccharide, in particular a capsular polysaccharide of Streptococcus pneumonia. The conjugate with improved immunogenicity can be used to prevent or treat diseases caused by pathogens, in particular diseases caused by coronaviruses.
Absstract of: WO2025108306A1
Disclosed are a VZV antigen variant, a nucleic acid, a pharmaceutical composition and the use thereof. The VZV antigen variant has a difference of Y582G compared to an amino acid sequence as set forth in SEQ ID NO: 1; and/or the VZV antigen variant has deletions at positions 561-623, 569-623 or 574-623 compared to an amino acid sequence as set forth in SEQ ID NO: 1; and/or the VZV antigen variant has a modification of a transmembrane region and intracellular region of a protein compared to an amino acid sequence as set forth in SEQ ID NO: 1, wherein the modification of the transmembrane region and intracellular region of the protein involves the replacement of a transmembrane region and intracellular region of an original VZV antigen with a transmembrane region of a SARS-CoV-2Spike protein or a transmembrane region of an influenza H protein. The VZV antigen variant has a stronger immunogenicity than the VZV antigen in the prior art, can achieve a higher titer of binding antibodies, and has a higher protection efficacy.
Absstract of: WO2025108530A1
The present invention describes the formulation of a phytotherapy product, namely an inhalable solution developed from a natural extract of quercetin, either alone or in combination with resveratrol, rigorously selected for their synergistic effects on the respiratory system and their potential in alleviating symptoms associated with respiratory diseases such as asthma, COPD, lung cancer, COVID-19, and long COVID. The solution is intended to be inhaled using a nebuliser or other inhalation device intended to transform the solution into an aerosol in order to have a direct effect on the bronchi and minimise side effects. Quercetin has anti-inflammatory, antioxidant, immunomodulatory, and antiviral properties. This document describes, through various examples, the manufacturing process developed to obtain a solution for inhalation.
Absstract of: WO2025111412A1
Small anti-inflammatory peptide for blocking NF-κB are disclosed herein. The peptides as well as compositions including the peptides can be administered to inhibit cytokine production and/or inhibit pulmonary inflammation in a subject in need. Particularly embodiments include administration to a subject suffering from coronavirus disease 2019 (COVID-19).
Absstract of: WO2025109176A1
This invention relates to Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-CoV-2, including SARS-CoV-2 variants, and SARS-CoV- 1, and affinity matured variants thereof. The binding agents, in particular the antibodies and antibody fragments, have one or more favourable antibody development characteristics. The invention also relates to methods using these binding agents and uses thereof.
Absstract of: US2025171546A1
Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods include administration of combinations of agents, including combinations that include dupilumab. The methods can be used to treat subjects diagnosed with a SARS-CoV-2 infection, including those already hospitalized to treat COVID-19 and/or those also having lymphopenia, to reduce the severity of outcomes related to COVID-19, such as admittance to the intensive care unit (ICU), mechanical ventilation, and/or death, particularly over periods of time longer than a month or two months following the initial administration of the agents. Compositions for use in the treatment of COVID-19 are also described.
Absstract of: US2025171449A1
The invention relates to tryptanthrin derivatives with thiosemicarbazone substitution of the general formulae I and II, where R1-R8 are independently H, OH, alkyl with 1 to 6 carbon atoms, C(CH3)3, allyl, propargyl, ben-zyl, phenyl, F, Cl, Br, I, CH2OH, O (alkyl), CF3, OCF3, CN, COOH, COO(alkyl), CONH2, CONH(alkyl), NO2, N(alkyl)2, NH(alkyl), NHCO(alkyl), where the alkyl has 1 to 6 carbon atoms, or R1-R2 or R2-R3 or R3-R4 or R5-R6 or R6-R7 or R7-R8 is —CH═CH—CH═CH—, i.e., a fused benzene ring, X and Z are independently H, alkyl of 1 to 6 carbon atoms, benzyl or phenyl. The compounds combine a structural motif suitable for PLpro targeting, have strong affinity and selectivity for RNA over DNA, and at the same time effectively chelate ferric and ferrous ions. Thus, these compounds have the desired properties for potential use as inhibitors of the production of SARS-COV-2 viral particles and can thus be used for the preparation drugs for the treatment of coronavirus diseases, especially COVID-19.
Absstract of: US2025171486A1
The present disclosure relates to N4-isobutyryloxycytidine analog synthesis and to the anti-viral use thereof against dengue virus, influenza virus, and SARS-COV-2 virus.
Absstract of: US2025171862A1
Methods for the rapid detection of the presence or absence of SARS-CoV-2, influenza A and influenza B in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2, influenza A, and influenza B and kits are provided that are designed for the detection of SARS-CoV-2, influenza A and influenza B.
Absstract of: US2025169661A1
Device to close a toilet lid before flushing contains a base part (2) in which a drive device in form of an electrical motor (7) is situated. On top of the base part (2) a motion detector (5) is located that controls a movable arm (3). Within the base part a motherboard (6) is situated. With help from the movement that emerge when flushing the motion detector (5) is activated, that in turn activates the electrical motor (7) that is connected with the movable arm (3) on the front side of the base part (2). The arm (3) opens up 45 degrees, pushes the toilet lid and returns to the origin mode. The detector (4) senses that the lid is no longer resting against the base part (2) and shuts of the device (1). In this way the source of the power consumption, which is a rechargeable battery (3), is limited. The lid is closed completely before flushing and bacteria, virus and the spread of Covid 19 is reduced.
Absstract of: US2025170084A1
This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally. The intermediate phase may be while the patient's breathing is being assisted mechanically.
Absstract of: US2025171864A1
The present invention relates to a rapid method to perform reverse transcription loop-mediated isothermal amplification (RT-LAMP) and LAMP at room temperature between 25-42° C., more specifically at 25-37° C., to detect RNA/DNA in a sample and a reagent kit thereof. Further, the invention relates to an in vitro method to detect SARS-CoV2 using RT-LAMP at room temperature between 25-42° C., more specifically at 37° C. The reagent kit comprises of enzymes/proteins—Klenow exo−/−, ApaI, High fidelity Taq Pol, Rpa32, StpA, AMV-RT for reverse transcriptase; buffer composition of—Tris-HCl, MgSO4, KCl, DTT, PEG, DMSO, 1 mM dNTPs each, at least 4 primers, and fluorescent or colorimetric dye.
Absstract of: US2025170246A1
Compositions and methods are disclosed for treating coronavirus infections, such as SARS CoV-2 coronavirus infections. For example, a composition is disclosed that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline (CDP-CHO), CDP-ethanolamine (CDP-ETH), and CDPdiacylglycerol (CDP-DAG) in combination with one or more agents for treating COVID-19, such as corticosteroids, antibodies, or antivirals, in a pharmaceutically acceptable carrier. Also disclosed is a method of treating coronavirus (e.g. SARS CoV-2) infection in a subject that involves administering to the subject one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline (CDP-CHO), CDPethanolamine (CDP-ETH), and CDP-diacylglycerol (CDP-DAG) in combination with agents for treating COVID-19, such as corticosteroids, antibodies, or antivirals.
Absstract of: US2025171511A1
Antiviral peptides and formulations thereof are described for use in treating or preventing one or more symptoms of coronavirus infections. Peptides derived from human beta defensin 2 have been shown to have antiviral properties against different variants of coronavirus including cross-linking viral particles, blocking cell-to-cell fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via intranasal route to prevent or alleviate one or more symptoms of coronavirus infections such as reducing the syncytial formation and lung damage.
Absstract of: WO2024018364A1
Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.
Absstract of: EP4560021A1
The present invention relates to an RNA encoding the S protein of SARS-COV-2, a vaccine comprising the RNA, and uses thereof. The present invention also relates to a universal polynucleotide molecule comprising a 5'-UTR and/or a 3'- UTR, and a nucleic acid sequence encoding a protein and/or polypeptide of interest, and optionally comprising a polyA.
Absstract of: EP4560010A1
The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.
Absstract of: ZA202407723B
The present disclosure provides a method for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection on the basis of receptor binding, including: subjecting crosslinked agarose as a matrix to surface carboxyl modification to obtain a magnetic agarose microsphere, and covalently coupling the magnetic agarose microsphere with a receptor protein to obtain a receptor protein-coupled magnetic agarose microsphere; allowing the receptor protein covalently binding to a surface of the receptor protein-coupled magnetic agarose microsphere to recognize and bind to a receptor-binding domain (RBD) of an outer membrane protein S of a SARS-CoV-2 sample, which simulates a binding process of the SARS-CoV-2 to a host cell to capture the SARS-CoV-2; subjecting the magnetic microsphere to washing, purification, and elution successively to obtain the SARS-CoV-2 with a cell binding ability; and detecting by an immunobinding-fluorescence quantitative polymerase chain reaction (PCR) combination, and evaluating infectivity and transmissibility of the SARS-CoV-2. The method is suitable for evaluating the replication and transmission of the SARS-CoV-2 in a patient infected with the SARS-CoV-2 during a treatment process and the infectivity of the SARS-CoV-2 carried by a patient with relapse symptoms after recovery.
Absstract of: MA61946B1
The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Absstract of: WO2025106792A1
Provided herein is a stable mutant coronavirus spike protein stem domain in a prefusion conformation comprising: an S2 subunit only, that has been modified to comprise; at least one additional intra-monomeric disulfide bond that stabilizes the S2 subunit; and 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus pre-fusion, S2-only spike protein maintains the prefusion conformation. Coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, existing variants, or an emerging variant thereof.
Absstract of: WO2025106738A1
Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can result in an improved immune response as compared to current SARS-COV-2 vaccines.
Nº publicación: WO2025106425A1 22/05/2025
Applicant:
UNIV FLORIDA [US]
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Absstract of: WO2025106425A1
The disclosure provides a composition comprising a nucleic acid encoding a human alpha coronavirus (HCoV) receptor binding domain (RBD) peptide and a severe acute respiratory syndrome coronavirus 2 (SCoV2) RBD peptide.
BOPI
Electronic site
